[Complications of chemotherapy in combination with bevacizumab for treating metastatic colorectal cancer]
- PMID: 21137245
[Complications of chemotherapy in combination with bevacizumab for treating metastatic colorectal cancer]
Abstract
Ninety-six patients with unresectable or metastatic colorectal cancer received first-line chemotherapy plus bevacizumab. The purpose of our study was to evaluate the safety and efficacy of the therapy. Median relapse-free survival lasted 10.4 months. Addition of bevacizumab was well tolerated and may be recommended for clinical use.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical